Angelini Pharma continues its commitment to HPAPI services

INTRODUCTION
The percentage of HPAPI drug candidates in the clinical development is rising steadily, owing to the rapid growth in small molecule cytotoxic compounds and antibody drug conjugates (ADCs) targeted therapies for oncology indications. Overall, cancer drugs as a class account for the greatest share of the global HPAPI market. The oncology-focus R&D pipeline growth is driving the CDMO industry to invest into small- and large-volume HPAPI facilities to gear up its ability to support current and future pharma outsourcing demands.